Sarcoma is rare kind of cancer that occurs in the connective tissues of the body. Normal connective tissue include blood vessels, fat, nerves, muscles, deep skin tissues, bones, and cartilage. There are more than 50 types of sarcomas. However, they are mainly classified into two types: soft tissue sarcomas and bone sarcomas. They are further divided based on presumed cell of origin found in the tumor. Soft tissue sarcoma is the most common type of sarcoma, accounting for more than 80% of all sarcoma cases. Sarcoma affects all age groups but is more common in children. It is estimated that about 15% of cancer diagnosis in children are sarcomas. Rise in the incidence and prevalence of sarcoma, strong clinical pipeline of sarcoma drugs, rise in government initiatives toward orphan drug development, and increase in research and development expenditure are likely to fuel the growth of the global sarcoma market during forecast period. However, disappointing results of promising pipeline molecules, high cost of treatment and side effect associated with it, and stringent government regulations are estimated to hamper the growth of the global sarcoma market in in the coming years.

Report Overview: https://www.transparencymarketresearch.com/sarcoma-market.html

The global sarcoma market can be segmented based on type, treatment, and geography. Based on type, the sarcoma market can be segmented into soft tissue sarcoma and bone sarcoma. The soft tissue sarcoma segment is expected to hold a significant share of the market during forecast period, owing to high incidence and prevalence rate of soft tissue sarcoma. In terms of treatment, the global sarcoma market can be categorized into chemotherapy, surgery, radiation therapy, and others (stem cell therapy). The chemotherapy segment generally includes a combination of various anti-neoplastic drugs. The commonly used chemotherapeutics agents are dactinomycin, etoposide, irinotecan, doxorubicin, carboplatin, ifosfamide, vincristine, among others. The chemotherapy segment expected to account for a significant share of the market during forecast period due to high cost of chemotherapy and it preference as the first line therapy for the treatment of sarcoma. Rise in the incidence and prevalence of sarcoma, increase in demand for targeted therapy and personalized therapy, and significant pipeline molecules (such as afatinib and temsirolimus) are likely to propel the market in the near future. Furthermore, development of new products with improved efficacy as a part of growth strategies adopted by a number of players and strategic deals, mergers, and acquisitions in the sarcoma market are estimated to drive the market in the next few years.

In terms of geography, the global sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to be a dominant region of the market, followed by Europe. The high incidence of sarcoma (around 15,000 new cases are diagnosed each year in the U.S.), growing awareness among people, increase in research and development expenditure, strong clinical pipeline, and well-established health care infrastructure contribute to the growth of the sarcoma market in North America. The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. The market is likely to be driven by India and China, owing to a significant patient base, increased government initiatives, and developing health care infrastructure. The market in Latin America and Middle East & Africa is anticipated to expand during the forecast period, owing to an increase in investments from market players in these regions and increase in prevalence of sarcoma.

Obtain the Report Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=52404

The leading players in the global sarcoma market include Eli Lilly and Company, CytRx, Boehringer Ingelheim, Ovation Pharmaceuticals, Inc., Pfizer, Tracon Pharma, Karyopharm Therapeutics, Blueprint Medicines, Advenchen Laboratories, Oasmia Pharmaceutical, and Arog Pharmaceuticals.

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com